Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases

Table 1 Investigational histone deacetylases inhibitors in pancreatic cancer patients

HDAC1 specificity	Intervention	Clinical trial phase	Study start date	Status	Clinical trial reference code
Pan-HDAC	Vorinostat + Marizomib	I	March 2008	Completed	NCT00667082
Pan-HDAC	Vorinostat + Capecitabine + Radiation Therapy	I	October 2009	Completed	NCT00983268
Pan-HDAC	Vorinostat + Gemcitabine + Sorafenib + Radiation Therapy	I	January 2015	Active	NCT02349867
Pan-HDAC	Vorinostat + Radiation Therapy	I and II	March 2009	Terminated	NCT00831493
Pan-HDAC	Vorinostat + 5-fluorouracil + Radiation Therapy	I and II	August 2009	Terminated	NCT00948688
Pan-HDAC	Panobinostat + Bortezomib	II	September 2010	Terminated	NCT01056601
Class I	Entinostat	I	March 2001	Completed	NCT00020579
Class I	Entinostat + Nivolumab	II	November 2017	Completed	NCT03250273
Class I	Entinostat + ZEN003694	I and II	March 2022	Not yet recruiting	NCT05053971
Class I	Entinostat + Molibresib	I	September 2020	Withdrawn	NCT03925428
Class I	Entinostat + FOLFOX2	I	January 2021	Withdrawn	NCT03760614
Class I	Tacedinaline + Gemcitabine	II	October 1999	Completed	NCT00004861

¹HDAC: Histone deacetylases.

²FOLFOX regimen consists of folinic acid, 5-fluorouracil, and oxaliplatin.